Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-07 13:58:06 - browse：1186

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Biogen’s boardroom scandal saddles CEO with first crisis

leisure time

focus

WSS

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Measles policy set amid Florida outbreak alarms vaccine proponents

New CMS data security rules will hurt Medicare, Medicaid research

Measles policy set amid Florida outbreak alarms vaccine proponents

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

focus

Wikipedia

hotspot

Medicare details structure of new drug price negotiation program

Be careful with at

Drug repurposing or repositioning? The language matters

New CMS data security rules will hurt Medicare, Medicaid research

23andMe had bad news about my health. I wish a person had delivered it

Treatments for cramps don't cut it. Why aren't there better options?

Wildfire smoke exposes gaps in outdoor worker protections

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Psychedelics group wrestles with new pharma identity

As AI regulations shape up, health tech startups beg for clarity

hotspot

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Biden administration begins canceling student loan debt for 804,000 borrowers

After Optum profits sink, UnitedHealth makes changes

Senators push IRS to launch nonprofit hospital probe

Senators push IRS to launch nonprofit hospital probe

FDA warns medical device makers about rise in fabricated data

leisure time

Wikipedia

focus

knowledge